ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2087

Kidney Tissue Damage in Mice with Single and Combined Abnormalities in Complement, Interferon and Apoptotic Cell Clearance

Sladjana Skopelja-Gardner1, YuFeng Peng2, Payton Hermanson2, Lucrezia Colonna2, Xizhang Sun3, Lena Tanaka4, Anne Davidson5, David Salant6 and Keith B. Elkon7, 1Division of Rheumatology, Department of Medicine, University of Washington, Seattle, WA, 2Division of Rheumatology, University of Washington, Seattle, WA, 3Rheumatology, University of Washington, Seattle, WA, 4Medicine/Rheumatology, University of Washington, Seattle, WA, 5Autoimmunity and Musculoskeletal Diseases, Feinstein Institute for Medical Research, Manhasset, NY, 6Boston University, Boston, MA, 7University of Washington, Seattle, WA

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: apoptotic clearance, autoantibodies, complement deficiency and lupus nephritis, Lupus

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, October 23, 2018

Title: Systemic Lupus Erythematosus – Animal Models Poster

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose:

Lupus nephritis (LN) affects ~70% of systemic lupus erythematosus (SLE) patients and is one of the main contributors to morbidity and mortality. While defective clearance of apoptotic cells (AC), autoantibodies, and type 1 interferons (IFN-I), are strongly implicated in lupus pathogenesis, the precise way that each impacts kidney protection and injury is unknown.

Methods:

To investigate mechanisms of kidney injury in a lupus-like disease model, we created C57BL/6 mice with defective clearance of AC (Mfge8-/-) and anti-chromatin antibodies (sle1) that were also deficient in either C1q [C1q Triple mutant (C1qTM)] or C3 (C3TM). Kidney injury was evaluated by urine albumin/creatinine ratio (UACR), PAS staining, and immunofluorescence (IF) staining. The effect of IFN-I on disease was studied in C3TM mice by a single injection of an adenovirus expressing IFNα (AdV-IFNα).

Results:

Sle1 mice deficient in MFG-E8 developed significantly higher titers of autoantibodies directed at lupus antigens compared to sle1 mice alone. When Mfge8-/-Sle1 mice also had C1q or C3 deficiency, a further increase in anti-DNA and other autoantibodies was observed. Both TM strains showed AC accumulation in the kidneys and C1qTM mice had decreased survival. Remarkably, we detected glomerular deposition of C3/C3d in C1qTM and the membrane attack complex (MAC) in C3TM mice. To dissociate the effects of complement on B cells versus effects on the kidney, we studied the impact of defective AC clearance and complement deficiencies on kidney injury in double knockout (DKO) (Mfge8-/-C1q-/- or Mfge8-/-C3-/-) mice using Nephrotoxic Nephritis model (NTN). NTN in C1qDKO and C3DKO mice revealed a significantly elevated UACR compared to the single mutants, i.e. worse kidney disease. This effect was independent of antibody deposition in the kidney as similar IgG levels were detected in all NTS-treated strains. IF analyses revealed glomerular C3/C3d deposition in C1qDKO mice and MAC deposition in C3DKO mice. A single injection of AdV-IFNα accelerated kidney damage in C3TM mice, resulting in high anti-dsDNA IgG titers, UACR, renal IgG deposition, and PAS staining.

Conclusion:

These findings demonstrate that, in the context of reduced clearance of AC, early complement components have two distinct functions: they prevent enhanced B cell autoreactivity and protect against kidney disease. Increased glomerular C3/C3d deposition in C1qTM and NTN C1qDKO mice suggest activation of the lectin or alternative complement pathways following AC accumulation. Increased MAC deposition in C3TM and NTN C3DKO mice indicates that, in the absence of C3 and presence of AC, a C3–independent mechanism leads to distal complement activation and MAC formation. This effect is further exacerbated by IFNα suggesting a mechanism of disease progression in human SLE in the context of C3 absence and/or consumption. These data prompt models of tissue injury in low complement states that will require assessment in human SLE and provide two distinct perspectives: i) a rationale for targeted therapeutics that are not currently used and ii) a cautionary note about the use of current complement inhibitor therapies.


Disclosure: S. Skopelja-Gardner, None; Y. Peng, None; P. Hermanson, None; L. Colonna, None; X. Sun, None; L. Tanaka, None; A. Davidson, None; D. Salant, None; K. B. Elkon, Amdax Theraputics, 2, 6.

To cite this abstract in AMA style:

Skopelja-Gardner S, Peng Y, Hermanson P, Colonna L, Sun X, Tanaka L, Davidson A, Salant D, Elkon KB. Kidney Tissue Damage in Mice with Single and Combined Abnormalities in Complement, Interferon and Apoptotic Cell Clearance [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/kidney-tissue-damage-in-mice-with-single-and-combined-abnormalities-in-complement-interferon-and-apoptotic-cell-clearance/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/kidney-tissue-damage-in-mice-with-single-and-combined-abnormalities-in-complement-interferon-and-apoptotic-cell-clearance/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology